Software-Defined In-Silico Design of Biomimetic Nanomaterials
Computational IP for payload-free nanoparticle surface engineering. InverseNano generates computational design intelligence, surface-engineering blueprints, and protectable in-silico IP for research teams and laboratories to evaluate, synthesize, validate, and commercialize.
We do not manufacture nanoparticles. We do not produce drugs. We do not conduct wet-lab synthesis or clinical validation.
You provide the biological target. We provide the computational nanomaterial design hypothesis.
Interactive In-Silico Locking Visualization
Computational surface-design hypothesis: can an engineered nanoparticle geometrically and energetically lock onto a disease-relevant protein receptor?
Software / In-Silico IP Only
Partners synthesize, validate, and commercialize.
Conceptual in-silico visualization of nanoparticle–receptor surface locking. InverseNano provides software-generated design and computational IP only. Laboratory synthesis and validation are performed by partners.
A Software / In-Silico IP Company
InverseNano uses computational inverse design to create candidate surface architectures for biomimetic nanoparticles that may be evaluated against disease-relevant protein receptors.
Platform Outputs
Our platform converts biological target structures into computational design assets ready for partner-side evaluation and validation.
- Computational nanomaterial design candidates
- Receptor-matching surface geometry hypotheses
- In-silico blockage and stability metrics
- Synthesis-aware design parameters
- IP-ready computational invention packages
What We Are Not
- InverseNano is not a pharmaceutical manufacturer.
- InverseNano is not a wet-lab nanomaterial synthesis company.
- InverseNano is not a clinical-stage drug developer.
InverseNano does not claim therapeutic efficacy, safety, regulatory approval, or clinical performance. All outputs are in-silico computational design assets intended for laboratory validation by qualified partners.
Why Traditional Discovery Stalls
Nanomedicine and biomaterial discovery often depends on constraints that computational design can address upstream.
Experimental Trial and Error
Long cycles of synthesis, screening, failure analysis, and redesign slow the path from target identification to viable candidates.
Payload-Dependent Chemistry
Many approaches rely on toxic or complex payload mechanisms rather than engineered surface interaction.
Limited Early-Stage Design Intelligence
Before synthesis begins, teams often lack a precise computational hypothesis for surface geometry, receptor coverage, and structural resilience.
Computational Inverse Design for Surface Engineering
InverseNano works from the biological target backward — generating candidate biomimetic nanoparticle surface designs intended to match the spatial and interaction constraints of the receptor.
The output is not a final drug.
The output is a computational design package — software-generated surface-engineering intelligence ready for partner-side evaluation.
Given a target protein structure, our software generates candidate surface architectures with synthesis-aware parameters, in-silico stability metrics, and receptor-matching geometry hypotheses — all packaged as protectable computational IP.
What the In-Silico Design Package Enables
InverseNano delivers a software-generated design package that partners can use before entering expensive wet-lab cycles.
Our output is not a final drug, manufactured nanoparticle, or clinical product. It is a computational design and IP-support package intended to help qualified partners evaluate, validate, and develop payload-free nanoparticle surface concepts.
Internal R&D Decision-Making
Use the design package to evaluate whether a biological target is suitable for payload-free nanoparticle surface engineering before committing to costly synthesis or screening work.
Partner-Side Blinded Laboratory Validation
The package can support independent, partner-side validation studies where the computational design is tested under controlled laboratory conditions.
Patent / Invention Disclosure Preparation
The report can provide structured computational evidence for invention disclosure, including target rationale, surface-design hypothesis, predicted blockage behavior, and reproducible in-silico metrics.
Partner-Side Synthesis Planning
The design output may help laboratory partners plan early synthesis feasibility, including surface geometry, formulation direction, and synthesis-aware design parameters.
Early-Stage Nanomaterial Candidate Selection
Partners can use the package to prioritize which computational candidates deserve further experimental evaluation, reducing unnecessary trial-and-error cycles.
InverseNano provides Software / In-Silico IP only. Laboratory synthesis, biological testing, safety evaluation, and commercialization are performed by qualified partners.
Computational Deliverables
Every design package is evaluated against rigorous in-silico benchmarks and formatted for IP and laboratory handoff.
In-Silico Thermal Resilience
Computational assessment of structural stability before laboratory synthesis.
Blockage Efficiency Index
A software-generated estimate of receptor coverage and blockage potential.
BEI ≥ 99.8%
Synthesis-Aware Blueprints
Design parameters prepared to help laboratory partners evaluate feasibility for microfluidic or other nanomaterial synthesis workflows.
IP-Ready Design Reports
Each validated computational output can be packaged as an in-silico invention record, including target structure, design rationale, candidate geometry, predicted metrics, and reproducible computational evidence.
Partner-Led Validation, Software-Generated Design
We are expanding blinded computational validation on complex biological targets. The partner owns or controls the biological target and performs laboratory validation.
InverseNano Partners With
- Biotech research teams
- University laboratories
- CROs
- Nanomedicine groups
- Material science companies
- IP and technology transfer teams
Partner Responsibility
The partner owns or controls the biological target and performs all laboratory synthesis, validation, and commercialization activities.
InverseNano Delivers
The software-generated design package and computational IP foundation — including surface geometry hypotheses, in-silico metrics, and IP-ready invention records.
Collaboration Inquiries
Software / In-Silico IP Partnership
InverseNano works as a Software / In-Silico IP partner for payload-free nanoparticle surface design.
We do not accept direct clinical submissions, patient data, or regulated health information through this website.
For research collaboration, blinded validation, or target-specific computational feasibility review, please contact us by email.
After receiving your inquiry, we will share our collaboration terms, confidentiality process, and the required non-confidential target information for initial review.
Contact: research@inversenano.com
Based in Rocklin, California, USA.
Please do not send patient-identifiable information, clinical records, genomic reports, or confidential structural files before an NDA or written collaboration framework is in place.
Software / In-Silico IP Partnership
We are expanding blinded computational validation on complex biological targets through qualified research partners.
Contact us to discuss collaboration terms, confidentiality, and non-confidential target information for initial feasibility review.
No clinical submissions, patient data, or regulated health information accepted through this website.